Innovation Beyond Patents
Rating: Hold
Target Price: 194,80 SEK
Upside: -4,27%
AstraZeneca’s historic stability, oncology monopoly, and strong pipeline position it for growth toward its $80B 2030 revenue goal. Its European and Chinese footprint hedges against US Inflation Reduction Act risks. The recommendation is Hold with a fair value of 194.80 and bull case potential.
Analyst: Philip Bengtsson Hörnebrant
05/04/2026